United States securities and exchange commission logo

                         May 19, 2022

       Jay Venkatesan, M.D.
       President and Chief Executive Officer
       Angion Biomedica Corp.
       51 Charles Lindbergh Boulevard
       Uniondale, New York 11553

                                                        Re: Angion Biomedica
Statement on Form S-3
                                                            Filed May 16, 2022
                                                            File No. 333-264994

       Dear Mr. Venkatesan:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Abby
Adams at (202) 551-6902 with any questions.


                         Division of Corporation Finance

                         Office of Life Sciences
       cc:                                              Kenneth L. Guernsey,